Akari Therapeutics' Nomacopan Secures Expediated Review Tag For Blistering Skin Disorder

The FDA has granted Fast Track designation to Akari Therapeutics Plc's AKTX nomacopan to treat patients with moderate and severe Bullous Pemphigoid (BP).
Nomacopan has also been granted orphan drug designation for nomacopan to treat BP by the FDA and the European Medicines Agency (EMA).
Fast track is a process designed to facilitate the development and expedite the review of drugs.
BP is a severe orphan autoimmune inflammatory blistering skin disease wherein both terminal complement activation (via complement component C5), and the lipid mediator leukotriene B4 (LTB4) have a central role in driving the disease.
Akari's lead drug candidate, Nomacopan, is a C5 complement inhibitor that independently and specifically binds to and inhibits leukotriene B4 (LTB4) activity.
Price Action: AKTX shares are up 2.13% at $2.39 during the market trading session on the last check Wednesday.